Clinical Development of PD-1 Blockade in Hematologic Malignancies. Review uri icon

Overview

abstract

  • Clinical development of immune checkpoint inhibitors targeting the PD-1 pathway has led to clinical benefits for patients with multiple solid tumor and hematologic malignancies and has revolutionized modern oncology. High response rates to PD-1 blockade in patients with classical Hodgkin lymphoma and certain subtypes of non-Hodgkin lymphoma highlight an intrinsic biologic sensitivity to this strategy of treatment. Despite early success of checkpoint inhibitor and immunomodulatory drug combinations in phase 2 studies in multiple myeloma, safety concerns in patients treated with the combination of immunomodulatory drugs and checkpoint inhibitors in myeloma have stalled drug development in this space. Novel combination approaches exploring PD-1 inhibitors with epigenetic modifiers in leukemia are underway.

publication date

  • January 1, 2018

Research

keywords

  • Hematologic Neoplasms
  • Programmed Cell Death 1 Receptor

Identity

PubMed Central ID

  • PMC5785103

Scopus Document Identifier

  • 85041487863

Digital Object Identifier (DOI)

  • 10.1097/PPO.0000000000000297

PubMed ID

  • 29360725

Additional Document Info

volume

  • 24

issue

  • 1